


CORRECTION

Open Access



Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis

Nader Salari¹, Samira Jafari², Niloofar Darvishi², Elahe Valipour³, Masoud Mohammadi^{4*} , Kamran Mansouri⁵ and Shamarina Shohaimi⁶

Correction to: Diabetol Metab Syndr (2021) 13:110
<https://doi.org/10.1186/s13098-021-00733-5>

Following publication of the original article [1], the Table 2 reports incorrect data for some of the studies included in the analysis:

1. In the study by Davies et al. (row 3), the dose of liraglutide should read 3.0 mg instead of 0.3 mg.
2. In the study by Greenway et al. (row 6), it should read Naltrexone 16.0 mg + bupropion instead of Naltrexone + bupropion 16.0 mg, and Naltrexone 32.0 mg + bupropion instead of Naltrexone + bupropion 32.0 mg.
3. In the study by O'Neil et al. (row 9) it should read Lorcaserin 10 mg BID instead of Orlistat 120 mg BID, and Lorcaserin 10 mg QD instead of Orlistat 120 mg QD.

The authors apologize for such mistakes. The data and the script files used in the analysis are available as Additional files 1, 2 and 3 to all readers.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13098-022-00838-5>.

Additional file 1. Input data.

Additional file 2. Network meta analysis.

Additional file 3. R script.

Author details

¹Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³Zimagine Medical Genetics Laboratory, Avicenna St, Hamedan, Iran. ⁴Department of Nursing, School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁶Department of Biology, Faculty of Science, University Putra Malaysia, Serdang, Selangor, Malaysia.

Published online: 07 May 2022

Reference

1. Salari N, Jafari S, Darvishi N, Valipour E, Mohammadi M, Mansouri K, Shohaimi S. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. *Diabetol Metab Syndr*. 2021;13:110. <https://doi.org/10.1186/s13098-021-00733-5>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1186/s13098-021-00733-5>.

*Correspondence: Masoud.mohammadi1989@yahoo.com

⁴ Department of Nursing, School of Nursing and Midwifery, Kermanshah

University of Medical Sciences, Kermanshah, Iran

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.